In adults, the circulating levels of FGF21 increase under adverse lipid profiles, obesity, metabolic syndrome, impaired glucose tolerance, type 2 diabetes mellitus, or atherosclerosis [18], but in children its relationship with metabolic syndrome has not been confirmed [19]. This evidence concerns the gene FGF21 and metabolic syndrome.